Simulations Plus, Inc. (SLP)

In the past six months, Simulations Plus's stock experienced a 14% surge following strong Q2 fiscal year 2026 results, but the company cut its full-year EPS outlook. Strategic collaboration programs focused on AI-enabled modeling were announced. Industry leaders discussed responsible AI in Model-Informed Drug Development. The Rosen Law Firm encouraged investors to inquire about a securities class action investigation. News emerged of securities violations claims and a significant stock plummet following disappointing preliminary Q3 2025 results and the dismissal of its auditor. Simulations Plus outlined its fiscal year 2026 revenue target, emphasizing its strategy to advance AI and cloud integration. Bleichmar Fonti & Auld LLP announced an investigation into potential violations of federal securities laws.

Simulations Plus's cash flow generally follows the seasonality pattern of its revenue. The company has anticipated that its first-quarter revenue will be approximately 3% to 5% lower than the same period in the previous year.

Simulations Plus, Inc. specializes in developing software for pharmaceutical research and education, and provides consulting services to the pharmaceutical industry. Its major products include GastroPlus for predicting absorption, ADMET Predictor for ADMET modeling, DILIsym for indicating drug-induced liver injury hazards, MonolixSuite for modeling and simulation, and other products based on mechanistic and mathematical models. The company also offers Pro-ficiency, which provides simulation-based learning and compliance solutions.

Simulations Plus, Inc. generates revenue primarily from the USA, followed by EMEA and Asia Pacific. The company's headquarters are located in Research Triangle Park, North Carolina. The company operates with a remote-first workforce model.

Simulations Plus's brand reputation has been significantly impacted by securities fraud investigations, the dismissal of its auditor Grant Thornton LLP, and disappointing financial results and guidance cuts. Multiple law firms announced investigations into potential securities fraud and violations of federal securities laws. Grant Thornton publicly disputed Simulations Plus's account of the dismissal. Disappointing preliminary Q3 2025 results and subsequent cuts to fiscal year 2025 revenue guidance led to significant stock price drops and eroded investor confidence.

Simulations Plus, Inc. has a diverse ownership structure with institutional investors holding approximately 27.16% to 80.68% of the company's stock, insiders holding around 17.39% to 52.80%, and retail investors holding about 0.00% to 31.09%. Major institutional owners include First Light Asset Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Key individual owners include Virginia E. Woltosz, Walter S. Woltosz, and Ronald F. Creeley.